# Hemant Surgical (NSE: HSIL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/HSIL · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹551 Cr, it ranks 1762nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.

Its return on equity was 13.9% in FY26. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹785 Cr (+14.2% year on year) and net profit ₹99 Cr (+11.8%), on a consolidated basis. Promoters held 52.83% of the company as of 18 May 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹551 Cr |
| ROE | 13.9% (FY26) |
| ROCE | 19.5% (FY26) |
| Debt to equity | 0.36 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹785 Cr | +14.2% | ₹99 Cr | +11.8% | ₹15.36 |
| Q4 FY26 | ₹742 Cr | +5.3% | ₹115 Cr | +19.4% | ₹17.83 |
| Q3 FY26 | ₹634 Cr | −3.8% | ₹71 Cr | −21.1% | ₹11.04 |
| Q2 FY26 | ₹602 Cr | +0.4% | ₹76 Cr | +5.4% | ₹11.75 |
| Q1 FY26 | ₹688 Cr | +21.4% | ₹89 Cr | +40.5% | ₹13.73 |
| Q4 FY25 | ₹705 Cr | — | ₹97 Cr | — | ₹14.93 |
| Q3 FY25 | ₹658 Cr | — | ₹91 Cr | — | ₹13.99 |
| Q2 FY25 | ₹599 Cr | — | ₹72 Cr | — | ₹11.14 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹107 Cr | ₹8 Cr |
| FY24 | ₹106 Cr | ₹10 Cr |

## Shareholding (18 May 2026)

- Promoters: 52.83%
- Foreign institutions: 0.14%
- Domestic institutions: 19.94%
- Non-institutions: 27.10%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Amanta Healthcare](https://app.pivotnow.in/stock/AMANTA) | ₹182.55 | ₹709 Cr | 42.2 | — |
| [Wanbury](https://app.pivotnow.in/stock/WANBURY) | ₹187.00 | ₹653 Cr | 9.6 | — |
| [Prevest Denpro](https://app.pivotnow.in/stock/PREVEST) | — | ₹472 Cr | — | — |
| [HALEOS LABS](https://app.pivotnow.in/stock/HALEOSLABS) | ₹1,540.00 | ₹466 Cr | 26.9 | — |
| [Albert David](https://app.pivotnow.in/stock/ALBERTDAVD) | ₹795.00 | ₹454 Cr | — | — |
| [Asarfi Hospital](https://app.pivotnow.in/stock/ASARFI) | — | ₹446 Cr | — | — |

## Questions and answers

### What is the market cap of Hemant Surgical?

Hemant Surgical's market capitalisation is ₹551 Cr (₹551 Cr) at the 19 Oct 2026 close, ranking 1762nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Hemant Surgical?

Return on equity was 13.9% in FY26 and return on capital employed was 19.5% in FY26 (consolidated figures).

### Is Hemant Surgical a debt-free company?

No. Hemant Surgical's debt-to-equity ratio was 0.36 in FY26, with total debt of ₹3 Cr.

### What were Hemant Surgical's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Hemant Surgical reported revenue of ₹785 Cr, +14.2% year on year, and net profit of ₹99 Cr, +11.8% year on year.

### What is the shareholding pattern of Hemant Surgical?

As of 18 May 2026: promoters 52.83%, foreign institutions 0.14%, domestic institutions 19.94%, non-institutions 27.10%.

### Who are Hemant Surgical's competitors?

The listed Pharma & Healthcare companies closest to Hemant Surgical by market cap are Amanta Healthcare, Wanbury, Prevest Denpro, HALEOS LABS, Albert David and Asarfi Hospital.

### Is Hemant Surgical a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Hemant Surgical's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HSIL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.